Company TxCell CBOE EUROPE EQUITIES

Equities

0QTN

FR0010127662

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^EUR	-

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection.

TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Managers	Title	Age	Since
Caroline Courme IRO	Public Communications Contact	-	16-02-29
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Matthieu Allez PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-
Pierre Heimendinger PRN	Corporate Officer/Principal	61	-

Members of the board	Title	Age	Since
Duncan Mckay CHM	Chairman	-	19-02-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	23,195,394	1,045,009 ( 4.505 %)	0	4.505 %

Sangamo Therapeutics France SAS

Les Cardoulines HT1 Allée de la Nertière

06560, Valbonne

+33 4 97 21 83 00

http://txcell.com/

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.52%	122B
REGENERON PHARMACEUTICALS, INC.	+22.05%	116B
ARGENX SE	+22.18%	27.03B
BIONTECH SE	-21.96%	20.36B
GENMAB A/S	-16.89%	16.43B
BEIGENE, LTD.	-18.60%	15.91B
WUXI APPTEC CO., LTD.	-44.74%	15.6B
SAREPTA THERAPEUTICS, INC.	+62.64%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+3.20%	13.59B

Bio Therapeutic Drugs